MedTrace Logo

A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder

NCT03061630 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2022-03-08

No results posted yet for this study

Summary

Previously-untreated, high-risk (\>T3 and/or N+) muscle-invasive bladder cancer (MIBC) cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1

Conditions

  • Urinary Bladder

Interventions

DRUG

Gemcitabine

D1.8.15 : GEMCITABINE 1000MG/M2

DRUG

Cisplatin

D1: CISPLATIN 60G/M2

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • SEHOON PARK, MD,PhD · SamsungMedicalCenter

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-15
Primary Completion
2022-03-31
Completion
2022-06-30
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03061630 on ClinicalTrials.gov